



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/850,128	05/08/2001	Robert H. Getzenberg	076333/0238	1058

7590 10/21/2002

Stephen A. Bent
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

[REDACTED] EXAMINER

EPPS, JANET L

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1635

DATE MAILED: 10/21/2002

8

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.	09/850,128	Applicant(s)	GETZENBERG, ROBERT H.
Examiner	Janet L Epps-Ford, Ph.D.	Art Unit	1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 08 August 2002.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.
- 4) Claim(s) 4-15, 18-20, 25-28, 30, 31, 35-39 and 44-57 is/are pending in the application.
4a) Of the above claim(s) 4-14, 18-20, 23, 30, 31, 35-39 and 44-47 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 15, 22, 25-28 and 48-57 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some *
 - c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Response to Arguments

2. Claims 15, 22, 25-28, and 33-34 remain rejected, and claims 48-57 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, for the reasons of record set forth in the Official Action mailed 8-15-01.

Applicant's arguments filed 8-08-2002 have been fully considered but they are not persuasive. Applicants traverse the instant rejection by way of amending claim 15 to exclude the antibody directed to RCNL-1, such that amended claims 15 and 22 encompass antibodies against human renal nuclear matrix proteins and immunogenic fragments thereof, and canceling claims 29 and 33-34. Moreover, Applicants argue that this rejection has been obviated and rendered moot by means of Applicant's amendment.

Contrary to Applicant's assertions, Applicants have not specifically addressed the pending rejection. Applicants have amended the instant claims to recite antibodies directed against "a renal nuclear matrix protein or an immunogenic fragment thereof," however it remains that the specification as filed does not provide a sufficient written description of the claimed invention, in particular Applicants have not clearly defined structurally, the immunogenic fragments of the renal nuclear matrix proteins according to the present invention.

As stated in the prior Office Action, antibodies of the present invention include those that are capable of binding to (immunogenic) fragments of the renal matrix proteins of the present invention, wherein said fragment encompasses isolated fragments, and fragments of the claimed proteins embedded within another protein. The specification provides insufficient written description to support the genus of antibodies encompassed by the instant claims. Other than a range of iso-electric points (pI; for example, "about 9.30"), and range of molecular weights (for example, "about 53 kD"), the instant claims do not recite any particular structural amino acid sequence information that may be associated with the genus of polypeptides encompassed by the claimed invention.

See the January 5, 2001 (Vol. 66, No. 4, pages 1099-1111) Federal Register for the Guidelines for Examination of Patent Applications Under the 35 USC 112 ¶ 1, "Written Description" Requirement. These guidelines state that: "To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. An applicant shows possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that applicant was in possession of the claimed invention."

Art Unit: 1635

In the instant case, further experimentation is required to identify the immunogenic fragments of the renal nuclear matrix proteins of the present invention, and furthermore to identify the antibodies targeting these fragments. Therefore, Applicants have not demonstrated possession of the full scope of the claimed invention since further experimentation is required and it does not appear that the claimed invention as a whole was "ready for patenting" at the time of filing of the present invention.

3. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1635

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L Epps-Ford, Ph.D. whose telephone number is 703-308-8883. The examiner can normally be reached on M-T, Thurs-Friday 9:00AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703)-308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-746-5143 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Janet L Epps-Ford, Ph.D.
Examiner
Art Unit 1635

JLE
October 9, 2002

SEAN McGARRY
PRIMARY EXAMINER
1635

A handwritten signature consisting of a stylized 'S' and a curved line above it, positioned over a printed name and a number. The printed text "SEAN McGARRY" is in capital letters, with "PRIMARY EXAMINER" on the line below it. Below the printed text is the number "1635" handwritten in cursive.